Italfarmaco’s oral HDAC inhibitor givinostat has been approved in the US as a treatment for Duchenne muscular dystrophy (DMD), becoming the first non-steroidal option for patients with all ...
By focusing on innovative, long-lasting pain relief methods, Brixton is well-positioned to contribute to the shift away from opioid dependence. The company’s technologies align with the objectives of ...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developi ...
even modest elevations in blood pressure or inhibition of antihypertensive medication efficacy resulting from non steroidal anti-inflammatory drugs can be of significant clinical and public health ...
When a club "non-tenders" a player, it declines to give that player a contract for the upcoming season, thereby immediately making him a free agent. Players on the 40-man roster with fewer than six ...
This means that the trial of OC134 in human subjects may now proceed. OC134 is an eye drop medicine candidate indicated for the topical treatment of, e.g., moderate to severe allergic conjunctivitis, ...